Regional disparities marked
The analysis of the 2024 data reveals important territorial disparities. Compared to 2022, some regions record:
A significant decline (3 to 5 points) in Île-de-France, Provence-Alpes-Côte d’Azur, Center-Val de Loire and Reunion; a moderate drop (1 to 2 points) in Burgundy-Franche-Comté, Normandy and Pays de la Loire; stability in Occitanie, Hauts-de-France, Grand Est, Brittany, Auvergne-Rhône-Alpes and Martinique; in new Aquitaine and Corsica. Failing COVIR?
So how can we explain this continuous drop? Public Health France is advancing a surprising explanation: “Since 2020 and the COVID-19 epidemic, disturbances have been observed in sending invitations and in participation. From January 1, 2024, the sending of invitations is made by health insurance. For this year, data relating to the number of women invited is not available to date, health insurance is not able to provide them for the moment. ”
Note also that around 10 % of women in the target population use off -program screening. This practice, although contributing to the early detection of breast cancer, therefore does not fall within the framework of monitoring the performance of the PNDOCS.
A major public health issue
Recall that with approximately 61,000 new cases and 12,000 deaths estimated in 2023, breast cancer remains the leading cause of cancer and cancer death in women in France. Faced with this observation, the health authorities have offered all women since 2004 aged 50 to 74 “without high risk” free screening every two years, including a clinical examination, bilateral mammography and a second reading of normal stereotypes by an expert.
“Right to help to die”: what does the end of life bill contain?
Source: Health destination
